Mucopolysaccharidosis type 2

A lysosomal storage disease with multisystemic involvement leading to a massive accumulation of glycosaminoglycans and a wide variety of symptoms including distinctive coarse facial features, short stature, cardio-respiratory involvement and skeletal abnormalities. It manifests as a continuum varying from a severe form with neurodegeneration to an attenuated form without neuronal involvement.

Respiratory failure

A severe form of respiratory insufficiency characterized by inadequate gas exchange such that the levels of oxygen or carbon dioxide cannot be maintained within normal limits.


Total: 1

                      


(per page)
PMID (PMCID)
28540187
(5432659)
OTHER
Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II.
Ngu LH, Ong Peitee W, Leong HY, Chew HB.
Mol Genet Metab Rep. 2017;12:28-32.
Available evidence in Asian populations shows that Hunter syndrome has a mean age of onset of 2 to 5years and a life expectancy of 13years in more severely affected individuals, with respiratory failure reported as the leading cause of death.